Next Article in Journal
Palladium Catalyzed Allylic C-H Alkylation: A Mechanistic Perspective
Previous Article in Journal
Efficient In Vivo Selection of a Novel Tumor-Associated Peptide from a Phage Display Library
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 16
Issue 1
10.3390/molecules16010915
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

X-Ray Supramolecular Structure, NMR Spectroscopy and Synthesis of 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-ones Formed by the Unexpected Cyclization of 3-[1-(Phenyl-hydrazono)ethyl]-chromen-2-ones

by
Itzia I. Padilla-Martinez
1,
Irma Y. Flores-Larios
2,
Efren V. García-Baez
1,
Jorge Gonzalez
2,
Alejandro Cruz
1 and
Francisco J. Martínez-Martinez
2,*
1
Unidad Profesional Interdisciplinaria de Biotecnología del Instituto Politécnico Nacional, Av. Acueducto s/n, Barrio la Laguna Ticomán 07340, México D. F., Mexico
2
Facultad de Ciencias Químicas, Universidad de Colima, km 9 Carretera Coquimatlán-Colima, Coquimatlán Colima 28400, Mexico
*
Author to whom correspondence should be addressed.
Molecules 2011, 16(1), 915-932; https://doi.org/10.3390/molecules16010915
Submission received: 16 December 2010 / Revised: 8 January 2011 / Accepted: 18 January 2011 / Published: 21 January 2011
(This article belongs to the Section Molecular Diversity)
Browse Figures
Versions Notes

Abstract

:
The molecular structures of nine 3-methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one isomers, obtained by the oxidative cyclization of the corresponding 1-phenylhydrazono chromen-2-ones with copper acetate as catalyst, are reported. The molecular and supramolecular structures of the 8-chloro, 8-bromo- and 8-nitro isomers 2b-d, were established by X-ray diffraction. The halogenated isomers 2b and 2c are isomorphs, they crystallize as a triclinic system, space group P-1 with two molecules in the asymmetric unit. Compound 2d crystallizes as a monoclinic system, space group P21/m with two molecules in the unit cell. The 1-phenyl ring [Cg(4)] is almost perpendicularly positioned to the chromene-pyrazole ring system. This conformation is in agreement with the anisotropic NMR shielding effect exerted by the phenyl ring over H-9 in solution. The supramolecular architecture is almost controlled by C―H···A (A = O, π) and face to face π-stacking interactions. The observed π-stacking trend between chromene and pyrazole rings is given by the overlapping between the best donor and acceptor rings in each compound.

1. Introduction

Pyrazole and its derivatives are shown to possess important biological and pharmaceuticalactivities [1,2] such as antimicrobial [3,4], antiviral [5,6], anxiolytic [7,8] and anti-inflammatory [4,9] activities. They are also useful in agrochemical industry as herbicides [10,11] and insecticides [12].
The 1-phenylchromeno[4,3-c]pyrazol-4-ones are important pyrazole derivatives which have been used for the synthesis of inmunomodulatory drugs because of their interaction with the benzodiazepine central receptor [13]. Several methods of synthesis have been reported starting from arylidenechromones and hydrazine in basic media [14,15]; 3-CN-4-[(o-hydroxy)phenyl]-1-phenyl-3-methylpyrazole in ethanediol [16]; 4-substituted with –OH and –Cl 1-(phenylhydrazono)-chromen-2-ones by cyclization in acidic media [17]. To the best of our knowledge, this cyclization is not expected in the absence of a 4-positioned good leaving group, and the closest reported approach is the cyclization of 6-chloro-3-{1-[(2,4,6-trichlorophenyl)-hydrazono]-ethyl}-chromen-2-one in the presence of equimolar quantities of SbCl5 to obtain a 3-methyl-1-(2,4,6-trichlorophenyl)-1H-chromeno-[4,3-c]pyrazol-4-one similar to 2a in 86% yield [18] and the reaction of 1-(chloro(thiophen-2-yl)methylene)-2-phenylhydrazine with coumarin at reflux in chloroform and triethylamine to yield 1-phenyl-3-thiophen-2-yl-1H-chromeno[4,3-c]pyrazol-4-one [19]. In addition, it is worth mentioning that there are six related structures deposited in the CSD (Version of November 2008) [20] but only one discussed in the literature.
In this contribution the synthesis of 1-phenyl-chromeno[4,3-c]pyrazol-4-ones 2a-i through the oxidative cyclization of 3-(phenyl-hydrazono)-chromen-2-ones 1a-i with copper acetate as catalyst is reported (Scheme 1). The structures in solution by NMR as well as the molecular and supramolecular structures in the solid state, by monocrystal X-ray diffraction, are discussed.
Molecules 16 00915 g004 550
Scheme 1. Synthesis of 3-methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-ones 2a-i starting form 3-[1-(phenyl-hydrazono)-ethyl]-chromen-2-ones 1a-i.
Scheme 1. Synthesis of 3-methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-ones 2a-i starting form 3-[1-(phenyl-hydrazono)-ethyl]-chromen-2-ones 1a-i.
Molecules 16 00915 g004

2. Results and Discussion

2.1. Synthesis and Molecular Structure in Solution

In our efforts to crystallize hydrazone 1a from a saturated chloroform solution, crystals of 3-methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one 2a were spontaneously formed instead in 30% yield at RT. It is worthy to note that the cyclization reaction of 1a is not expected, because of the absence of a 4-positioned good leaving group to allow pyrazole ring formation. To ascertain the scope and limitation of this transformation, several 3-(phenyl-hydrazono)-chromen-2-ones 1b-i were tested but cyclization did not proceed under the same conditions as for 1a. This result lead us to use Cu(CH3COO)2·H2O as catalyst, since some examples of copper-catalyzed oxidative amination of alkynes [21] and azoles [22] via CH and NH coupling have recently been reported. Then, compounds 2a-i were prepared in poor to good yields (50–83%), starting from the corresponding 3-[1-(phenyl-hydrazono)-ethyl]-chromen-2-ones 1a-i, using Cu(CH3COO)2·H2O as catalyst in 20:1 weight ratio under mild conditions. In comparison with reported methods, starting from 4-hydroxybenzopyrano-arylhydrazones, the yields are lower or similar for 2a (76%) [17] and 2b (39%) [15], but in the case of 2c (78%) and 2d (83%) [23] they are significantly enhanced by the use of the copper catalyst.
The reaction should proceed by a simple intramolecular conjugate addition of the Ph-N to the α,β-unsaturated–C=N+ system, through the intermediate A, and the subsequent oxidation of the resulting dihydro-pyrazolone B (Scheme 2). This proposal is supported on similar reactions reported in acid media [24,25]. The formation of the key intermediate A’ would be disfavored either by electro withdrawing (W) or by electrodonating (D) substituents, which would explain the necessary aid of the copper catalyst (Scheme 3).
Molecules 16 00915 g005 550
Scheme 2. Proposed mechanism of reaction.
Scheme 2. Proposed mechanism of reaction.
Molecules 16 00915 g005
Molecules 16 00915 g006 550
Scheme 3. Resonance structures of 6-substituted-3-[1-(phenyl-hydrazono)-ethyl]-chromen-2-ones 1a-i with electrowithdrawing (W) or electrodonor (D) groups.
Scheme 3. Resonance structures of 6-substituted-3-[1-(phenyl-hydrazono)-ethyl]-chromen-2-ones 1a-i with electrowithdrawing (W) or electrodonor (D) groups.
Molecules 16 00915 g006
Several differences in the 1H- and 13C-NMR spectra appear as a consequence of the cyclization. Selected NMR and IR data are listed in Table 1 and Table 2 for 1a-i and 2a-i, respectively. The 1H-NMR spectra of compounds 2a-i is characterized by the loss of the H-4 signal, usually appearing as a singlet at δ 7.98–8.17, in the starting compounds 1a-i. In addition, the chemical shift of H-9 in 2a-i appears at δ 6.62–8.02, more shielded than the former H-5 (δ 6.97–8.51) in 1a-i, because of the anisotropic NMR shielding effect exerted by the phenyl group which should be almost perpendicular to the 1-phenyl-chromeno[4,3-c]pyrazol-4-one ring system in compounds 2a-f. The 13C chemical shift of C-3a appears at 106–107 ppm in compounds 2a-i, whereas the former C-3, in the starting hydrazones 1a-i, is at 127.8–130.6 ppm. Subtle shielding is also observed for C-9a (former C-10) by 7.0 ppm, in agreement with the aromatic character of the newly formed pyrazole ring. The chemical shift of C-9b (former C-4) remains almost the same even when in this position was performed the ring closure.
Table
Table 1. Selected NMR and IR spectroscopic data for hydrazones 1a-i.
Molecules 16 00915 i001
Table 1. Selected NMR and IR spectroscopic data for hydrazones 1a-i.
Molecules 16 00915 i001
δ 1Hδ 13Cν/cm−1
Comp.H-4H-5C-2C-3C-4C-10CO
1a8.167.81160.2127.9139.8119.91695, 1596
1b8.177.97159.2128.2137.8119.51703, 1598
1c8.158.08159.1128.3137.7116.11704, 1597
1d8.408.84159.2130.6137.7119.91726, 1604
1e7.986.97160.9127.9139.7120.11698, 1574
1f8.027.06160.2127.9140.0120.41700, 1601
1g7.957.34156.3128.8138.3116.91713, 1599
1h7.957.51159.2129.2137.6121.61707, 1530
1i7.967.41159.0129.7137.6121.61709, 1533
The saturation of the Me frequency in 1a (δ 2.20, s) gives a NOE effect on proton H-4 (δ 8.16, s) and NH proton (δ 9.43, s), suggesting an E configuration for the C=N double bond and thus the predominance in solution of the rotamer I (Scheme 4). Thus the transformation of 1a into 2a implies the breaking of the double –C=N– bond to a single –C–N– to allow the location of the atoms in the proper place for cyclization in agreement with the above mentioned copper-catalyzed oxidative amination.
Table
Table 2. Selected NMR and IR spectroscopic data for pyrazoles 2a-i.
Molecules 16 00915 i002
Table 2. Selected NMR and IR spectroscopic data for pyrazoles 2a-i.
Molecules 16 00915 i002
δ 1Hδ 13Cν/cm−1
Comp.H-9C-4C-3aC-9aC-9bCO
2a7.09158.3106.5112.0141.91726
2b7.03157.6106.8113.1140.71743
2c7.16157.6106.8113.7140.61742
2d8.02156.9106.8112.4143.61756
2e6.50158.4106.7112.1141.91734
2f6.65157.6106.6112.7142.11743
2g6.72156.7106.8113.7140.11744
2h6.90156.2106.8112.6140.21749
2i6.90156.2106.8114.0140.21750
Molecules 16 00915 g007 550
Scheme 4. Rotamers I-IV in solution and isomerization from E to Z in acid media.
Scheme 4. Rotamers I-IV in solution and isomerization from E to Z in acid media.
Molecules 16 00915 g007

2.2. Molecular and Supramolecular Structure in Solid State

1-Phenyl-chromeno[4,3-c]pyrazol-4-ones 2b-d were crystallized from saturated DMF solutions. The halogenated isomers 2b,c crystallize as a triclinic system, space group P-1 with two molecules in the asymmetric unit. Compound 2d crystallizes as a monoclinic system, space group P21/m with two molecules in the unit cell. A summary of bond lengths and angles are listed in Table 3 and crystal data and structure refinement for 2b-d are listed in Table 4. As in other coumarin derivatives, the replacement of Cl by Br does not alter the crystal packing [26]. All the atoms of pyrazole and chromenone rings lie in a single plane within the limits of experimental error. The 1-phenyl ring in compounds 2b-d is sterically hindered and appears twisted by 71.9(2)º, 74.7(5)º and 92.1(2)º, respectively, from the three ring fused coplanar chromeno[4,3-c]pyrazol-4-one system in agreement with the conformation observed in solution (vide supra). The torsion angle between both planes is very close to that observed for 1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one of 73.1(6)º [27]. However, in compound 2d the 1-phenyl ring [Cg(4)] is almost perpendicularly positioned, thus a symmetry plane cut the molecule through its equatorial plane and only one half of the phenyl ring is observed. This conformation is in agreement with the observed anisotropic NMR shielding effect exerted by the phenyl ring over H-9 in solution.
The molecular structures of the three isomers are very similar and the major differences among them arise from the nature of the 8-substituent, Figure 1. A brief comparison with the starting coumarins points out the lengthening of C9a―C9b bond length to 1.439(5) Å (mean value of 2b-d), from a mean reported value of 1.35 Å (C3―C4 in the former coumarins) [28], in agreement with a delocalized electronic character of the pyrazole ring.
Molecules 16 00915 g001 550
Figure 1. The molecular structures of 2b-d, from left to right, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level and H atoms are shown as small spheres of arbitrary radii.
Figure 1. The molecular structures of 2b-d, from left to right, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 30% probability level and H atoms are shown as small spheres of arbitrary radii.
Molecules 16 00915 g001
Because of the arrangement of the aromatic rings, the supramolecular architecture is almost controlled by C―H···A (A = O, π) and face to face π-stacking interactions, whose geometrical parameters are listed in Table 4. In the solid state C9―H9···Cg(4) and C9···Cg(4) distances, and C9―H9···Cg(4) angle, suggest an intramolecular C―H···π interaction S(6) in 2d, Figure 2. Even when these geometric parameters are similar among 2a-d, only those corresponding to 2d lie are in the proper range to be considered as such [29].
Table
Table 3. Selected bond lengths and angles from X-ray data of compounds 2b-d.
Molecules 16 00915 i003
Table 3. Selected bond lengths and angles from X-ray data of compounds 2b-d.
Molecules 16 00915 i003
2b X = Cl2c X = Br2d X = NO2
AtomsBond lengths (Å)
X(8)―C(8)1.732(2)1.894(4)1.466(2)
O(4)―C(4)1.200(2)1.197(6)1.189(2)
O(5)―C(4)1.385(2)1.385(6)1.404(2)
O(5)―C(5A)1.382(2)1.379(5)1.374(2)
N(1)―N(2)1.376(2)1.374(5)1.379(2)
N(1)―C(9B)1.346(2)1.353(5)1.345(2)
N(1)―C(10)1.433(2)1.428(6)1.433(2)
N(2)―C(3)1.321(2)1.315(6)1.315(2)
C(3)―C(3A)1.408(3)1.400(7)1.408(3)
C(3A)―C(4)1.435(3)1.441(6)1.441(3)
C(3A)―C(9B)1.384(2)1.378(5)1.380(2)
C(5A)―C(9A)1.402(3)1.389(6)1.403(3)
C(9A)―C(9B)1.437(3)1.438(5)1.442(2)
O(8B)―N(8) 1.195(3)
O(8A)―N(8) 1.204(2)
Bond angles (º)
C(4)―O(5)―C(5A)123.60(15)123.8(4)124.12(15)
N(2)―N(1)―C(9B)111.82(14)111.3(3)111.53(12)
N(2)―N(1)―C(10)118.91(15)119.8(4)121.02(14)
C(9B)―N(1)―C(10)129.18(15)128.9(3)127.44(14)
N(1)―N(2)―C(3)105.86(15)105.9(4)105.81(15)
C(3)―C(3A)―C(4)131.53(15)131.9(4)132.13(14)
C(3)―C(3A)―C(9B)106.46(16)106.5(4)106.24(15)
O(4)―C(4)―O(5)116.68(17)117.0(4)115.98(18)
O(5)―C(4)―C(3A)114.98(14)114.5(4)114.44(14)
X(8)―C(8)―C(7)119.13(15)119.0(4)119.30(18)
N(1)―C(9B)―C(3A)105.87(15)105.9(3)106.10(15)
Table
Table 4. Geometric parameters associated with D―H···A (A = O, π) interactions for compounds 2a–d.
Table 4. Geometric parameters associated with D―H···A (A = O, π) interactions for compounds 2a–d.
Comp.D―H···Aa (symmetry code)H···A/ÅD···A/ÅD―H···A/º
2abC6―H6···Cg(4) (x, y, 1 + z)2.893.820(3)178
C9―H9···Cg(4) (x, y, z)2.993.825(3)150(2)
C16―H16A···Cg(3) (−x, −½ + y, −z)2.75(3)3.6659(18)157
2bC13―H13···O4 (x, y, z − 1)2.4003.265(7)155
C15―H15···O5 (2 − x, 1 − y,1 − z)2.5703.443(6)157
C7―H7···Cg(4) (x, y − 1, z)2.573.460(2)161
C16―H16C···Cg(3) (1 − x, 1 − y, −z)2.783.535(2)136
2cC13―H13···O4 (x, y, z + 1)2.4503.340(7)161
C15―H15···O5 (−x, 1 − y, −z)2.5803.450(6)156
C7―H7···Cg(4) (x, 1 + y, z)2.723.631(5)167
C16―H16B···Cg(3) (1 − x, 1 − y, −z)2.873.633(5)137
2dC13―H13···O4 (x, y, z + 1)2.533.464(3)179
C7―H7···Cg(4) (1 + x, y, z)2.783.6999(3)171
C9―H9···Cg(4) 2.793.632(3)152
a Cg(3) the centroid of the benzenoid ring (C5AC9AC9C8C7C6C5A) and Cg(4) the centroid of the phenyl ring (C10―C15); b From reference 32.
Molecules 16 00915 g002 550
Figure 2. Supramolecular structure of compound 2d in the ac plane. S(6) intramolecular ring and C(8) chain forming bifacial C―H···π interactions, C(12) chain and R54(25) ring motifs are also observed.
Figure 2. Supramolecular structure of compound 2d in the ac plane. S(6) intramolecular ring and C(8) chain forming bifacial C―H···π interactions, C(12) chain and R54(25) ring motifs are also observed.
Molecules 16 00915 g002
The first dimension (1-D) is directed by C13—H13···O4C4 interactions, between an aromatic hydrogen and the oxygen of the lactone group, developing C(10) chains along the direction of the c axis in 2b-d. Molecules of 2b,c self assemble in the bc plane and 2d in the ac plane through C7―H7···Cg(4) interactions forming C(8) chains. The 2-D assembly is thus described as a R54(25) ring, in agreement with the graph set notation conventions [30], Figure 2. 2-D assembled monolayers of 2b,c and 2d are face-to-face π-stacked developing the 3-D along the a and the b axis, respectively. A C(12) chain motif complements the 3-D in compounds 2b,c through the participation of C15―H15···O5 and C16―H16B···Cg(3) contacts running along the direction of the a axis (Figure 3).
Molecules 16 00915 g003 550
Figure 3. Intermolecular interactions for molecule 2c in the ac plane. C(12) chain motif is observed through the participation of C15―H15···O5 and C16―H16B···Cg(3) contacts running along the direction of the a axis.
Figure 3. Intermolecular interactions for molecule 2c in the ac plane. C(12) chain motif is observed through the participation of C15―H15···O5 and C16―H16B···Cg(3) contacts running along the direction of the a axis.
Molecules 16 00915 g003
The participation of the N-phenyl ring [Cg(4)] in π-stacking is restricted to C―H···π interactions because of its disposition out of the plane. In contrast, the remaining pyrazole [Cg(1)], pyrone [Cg(2)] and benzenoid [Cg(3)] rings are lying in the same plane and thus are appropriately positioned for π-stacking. The geometric parameters associated with π-stacking interactions are listed in Table 5. Pyrazole ring is stacked with pyrone ring in compound 2a [Cg(1)···Cg(2)] [31], it further appears stacked with the Cl- or Br- substituted benzenoid ring [Cg(1)···Cg(3)] in compounds 2b and 2c. In both compounds, the π-stacking between pyrone and benzenoid rings, typical of coumarins, is also observed [Cg(2)···Cg(3)]. However, in the case of compound 2d only Cg(1) and Cg(3) are stacked, the EW group 8-NO2 diminishes the charge transfer capability of the benzenoid ring, enabling the formation of π-stacked centrosymmetric pairs with pirazole ring, the best charge transfer donor ring. In the other hand, the donor-acceptor capabilities of the benzenoid ring changes on going from 2a to 2d, according with the increase of the EW nature of the 8-substituent. Thus, the observed π-stacking trend between the rings is given by the overlapping between the best donor and acceptor ring in each molecule. This trend is consistent with those observed for other CCDC deposited structures [32], whose molecular and supramolecular analysis is missing (LOLZER, LOLZOB, LOLZUH, LOMBAQ, LOMBEU). Compounds 2a-2d are functional isomers but only 2b and 2c are isomorphous, however the supramolecular structure of all of them is almost the same, varying only in the π-stacked rings and the propagating directions of the supramolecular motifs.
Table
Table 5. Geometric parameters associated with π···π stacking interactions for compounds 2a–2d.
Table 5. Geometric parameters associated with π···π stacking interactions for compounds 2a–2d.
Comp.Centroidsa (symmetry code)Intercentroid distance/A°Dihedral angle/ºInterplanar distance/A°
2abCg(1)···Cg(2) (−x, −½ + y, −z)3.8508(9)0.0003.4916(1)
2bCg(1) · Cg(2) (1 − x, 1 − y, 1 − z)3.6117(10)0.30(8)3.3563(7)
Cg(1)···Cg(3) (2 − x, 1 − y, 1 − z)3.6664(11)1.33(9)3.3697(7)
Cg(2)···Cg(3) (2 − x, 1 − y, 1 − z)3.6345(11)1.23(8)3.4103(6)
2cCg(1)···Cg(2) (1 − x, 1 − y, 1 − z)3.708(2)0.3(2)3.4328(17)
Cg(1)···Cg(3) (−x, 1 − y, −z)3.727(2)1.0(2)3.4367(17)
Cg(2)···Cg(3) (−x, 1 − y, −z)3.6345(11)1.23(8)3.4103(6)
2dCg(1)···Cg(3) (1 − x, −½ + y, −z)3.8523(8)0.02(8)3.5032(7)
a Cg(1) is the centroid of the pyrazole ring (N1N2C3C3AC9B), Cg(2) the centroid of the pyrone ring (O5C4C3AC9BC9AC5A), Cg(3) the centroid of the benzenoid ring (C5AC9AC9C8C7C6C5A) and Cg(4) the centroid of the phenyl ring (C10-C15); b From reference 32 (LOLZUH).
It is noteworthy that in these compounds, neither –Cl, –Br or –NO2 substituents in the benzenoid ring nor the lactone carbonyl, are involved in dipole-dipole interactions [33,34]. This observation contrasts with most of the coumarins studied by our group, whose supramolecular architectures are strongly influenced by the participation of these groups in multicentered interactions [35,36].

3. Experimental

3.1. Materials and Methods

All chemicals and solvents were of reagent grade and used as received. The starting coumarins were synthesized as reported elsewhere [33]. Melting points were measured on an Electrothermal IA 9100 apparatus and were uncorrected. IR spectra were recorded neat using a Varian 3100 FT-IR EXCALIBUR series spectrophotometer. 1H- and 13C-NMR spectra were recorded on a Varian Mercury 300 (1H, 300.08; 13C, 75.46 MHz) instrument in CDCl3 solutions, unless otherwise is specified, chemical shifts are in ppm and coupling constants in Hz, measured with SiMe4 as internal reference. Mass spectra were obtained in a GC-MS system (Saturn 2100T) with an electron ionization mode (Hewlett-Packard 5972 series) using HP5. Elemental analyses were performed on a Perkin-Elmer 2400 elemental analyzer.

3.2. X-ray Data Collection and Structure Determination

Crystals suitable for X-ray analysis were obtained by slow crystallization from saturated DMF solutions. Single-crystal X-ray diffraction data for molecules 2b-d were collected on a Bruker Apex II area detector diffractometer at 293 K with Mo Kα radiation, λ = 0.71073 Å. A semiempirical absorption correction was applied using SADABS [37], and the program SAINT [37] was used for integration of the diffraction profiles. The structures were solved by direct methods using SHELXS97 [38] program of WinGX package [39]. The final refinement was performed by full-matrix least-squares methods on F2 with SHELXL97 program [37]. H atoms on C, N and O were positioned geometrically and treated as riding atoms, with C―H = 0.93–0.98 Å, and with Uiso(H) = 1.2Ueq(C). Mercury was used for visualization, molecular graphics and analysis of crystal structures [40], software used to prepare material for publication was PLATON [41]. Crystallographic data (excluding structure factors) for the structures in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication CCDC numbers 766071 2b, 766070 2c,766072 2d. Crystal data and details concerning data collection and structure refinement are given in Table 6.
Table
Table 6. Crystal data and structure refinement details for 2b-d.
Table 6. Crystal data and structure refinement details for 2b-d.
2b2c2d
Chemical formulaC17H11N2O2Cl1C17H11N2O2Br1C17H11N3O4
Mw310.7355.19321.2
Cell setting, Space group Triclinic, P-1Triclinic, P-1Monoclinic, P 21/m
a (A°)7.1177 (8)7.1681(8)9.4294(11)
b (A°)9.2540 (10)9.3210(11)7.0064(8)
c (A°)11.7266(13)11.8449(14)12.0294(14)
α (º)110.450(2)109.820(2)90
β (º)98.468(2)97.016(2)112.826(2)
γ (º)97.748(2)96.891(2)90
V (Å 3)701.14(8)727.83(15)732.50(7)
Z222
Density (mg cm−3)1.4711.6211.46
μ (mm−1)0.2812.8310.11
Crystal form, colorBlock, pale yellowBlock, colorlessBlock, pale yellow
Crystal size (mm3)0.48 × 0.22 × 0.190.40 × 0.20 × 0.200.45 × 0.33 × 0.30
No. of measured,609276524922
independent and316028532514
observed reflections284020132261
Rint0.0240.0540.024
θmax(°)28.32628.3
Refinement on F2F2F2
R[F2 > 2σ(F2)], wR(F2),S0.048, 0.116, 1.0890.057, 0.116, 1.0290.043, 0.122, 1.056
No. of reflections316028532514
No. of parameters200200218
Weighting scheme1/[σ2(Fo2) + (0.0542P)2 + 0.2899P]1/[σ2(Fo2) + (0.0542P)2 + 0.1266P]1/[σ2(Fo2) + (0.0576P)2 + 0.321P]
P = (Fo2 + 2Fc2)/3P = (Fo2 + 2Fc2)/3P = (Fo2 + 2Fc2)/3
Δρmax, Δρmin (eÅ−3)0.411, −0.2810.670, −0.3220.194, −0.199

3.3. General Methods of Synthesis

6-Substituted-3-[1-(phenylhydrazono)-ethyl]-chromen-2-ones 1a-i. were synthesized from phenyl-hydrazine and 0.5 g of the corresponding coumarins, following standard procedures. The syntheses of compounds 2a [15,17], 2b [15], 2c, 2d [23] have been reported elsewhere, albeit with lack of some spectroscopic data, thus for completeness purposes they are included but elemental analysis was performed only to the new compounds 2e-f.
3-[1-(Phenylhydrazono)-ethyl]-chromen-2-one (1a). Obtained from 3-acetyl-2H-1-benzopyran-2-one (0.5 g, 2.66 mmol) and phenylhydrazine (0.26 mL, 2.66 mmol) as an orange solid in 85% yield (0.633 g, 2.26 mmol), mp = 193–196 °C, IR νneat (cm−1): 3295 (N-H), 1695 (OC=O), 1596 (C=O), 1255, 1155 (C-O). 1H-NMR (DMSO-d6) δ: 9.43 (s, 1H, NH), 8.16 (s, 1H, H-4), 7.81 (d, 1H, H-5, 3J = 7.7), 7.57 (dd, 1H, H-7, 3J = 8.0, 7.5), 7.38 (d, 1H, H-8, 3J = 8.3, 3J = 8.3), 7.33 (t, 1H, H-6, 3J = 8.0, 7.6,4J = 2.2), 6.74–7.24 (m, 5H, Ph), 2.20 (s, 3H, CH3). 13C-NMR (DMSO-d6) δ: 160.2 (C-2), 153.6 (C-9), 146.2 (C-11), 139.8 (C-4), 139.2 (Ci), 132.2 (C-7), 129.5 (C-5), 129.5 (Cm), 127.9 (C-3), 125.2 (C-6), 120.0 (Cp), 116.4 (C-8), 119.9 (C-10), 113.7 (Co), 15.8 (Me). Anal. Calcd for C17H14N2O2; C, 73.37; H, 5.07; N, 10.12. Found: C, 73.27; H, 4.91; N, 10.12. m/z = 277.1 (M, 22%), 77 (20%).
6-Chloro-3-[1-(phenylhydrazono)-ethyl]-chromen-2-one (1b). Obtained from 3-acetyl-6-cloro-2H-1-benzopyran-2-one (0.5 g, 2.22 mmol) and phenylhydrazine (0.22 mL, 2.22 mmol) as an orange solid in 82% yield (0.578 g, 1.83 mmol), mp = 184–188 °C, IR νneat (cm−1): 3300 (N-H), 1703 (OC=O), 1598 (C=O), 1251, 1155 (C-O), 810 (C-Cl). 1H-NMR (DMSO-d6) δ: 9.49 (s, 1H, NH), 8.17 (s, 1H, H-4), 7.97 (d, 1H, H-5, 4J = 2.3), 7.57 (dd, 1H, H-7, 3J = 8.8, 4J = 2.3), 7.43 (d, 1H, H-8, 3J = 8.8), 6.75–7.25 (m, 5H, Ph), 2.20 (s, 3H, CH3). 13C-NMR (DMSO-d6) δ: 159.2 (C-2), 151.6 (C-9), 145.4 (C-11), 138.1 (Ci), 137.8 (C-4), 130.9 (C-7), 129.0 (C-6), 128.8 (Cm), 128.2 (C-3), 127.7 (C-5), 120.8 (Cp), 119.5 (C-10), 117.8 (C-8), 113.1 (Co), 15.0 (Me). m/z = 312 (M, 30%), 313 (8%), 240 (8%), 77 (28%).
6-Bromo-3-[1-(phenylhydrazono)-ethyl]-chromen-2-one (1c). Obtained from 3-acetyl-6-bromo-2H-1-benzopyran-2-one (0.5 g, 1.87 mmol) and phenylhydrazine (0.18 mL, 1.87 mmol) as an orange solid in 67% yield, (0.451 g, 1.25 mmol), mp = 184–186 °C, IR νneat (cm−1): 3301 (N-H), 1704 (OC=O), 1597 (C=O), 1250, 1158 (C-O), 681 (C-Br). 1H-NMR (DMSO-d6) δ: 9.48 (s, 1H, NH), 8.15 (s, 1H, H-4), 8.08 (d, 1H, H-5, 4J = 2.3), 7.68 (dd, 1H, H-7, 3J = 8.8, 4J = 2.3), 7.35 (d, 1H, H-8,3J = 8.8), 6.75–7.23 (m, 5H, Ph), 2.17 (s, 3H, CH3). 13C-NMR (DMSO-d6) δ: 159.1 (C-2), 152.0 (C-9), 145.4 (C-11), 138.1 (Ci), 137.7 (C-4), 133.8 (C-7), 130.8 (C-5), 128.9 (Cm), 128.3 (C-3), 121.3 (C-6), 119.5 (Cp), 118.1 (C-8), 116.1 (C-10), 113.1 (Co), 15.0 (Me). m/z = 356 (M, 100%), 358 (30%), 357 (20%), 278 (5%), 77 (27%).
6-Nitro-3-[1-(phenylhydrazono)-ethyl]-chromen-2-one (1d). Obtained from 3-acetyl-6-nitro-2H-1-benzopyran-2-one (0.5 g, 2.14 mmol) and phenylhydrazine (0.21 mL, 2.14 mmol) as an orange solid in 53% yield (0.370 g, 1.14 mmol), mp = 204–206 °C, IR νneat (cm−1): 3328 (N-H), 1726 (OC=O), 1604 (C=O), 1516, 1340 (C-NO2), 1239, 1113 (C-O). 1H-NMR (DMSO-d6) δ: 9.55 (s, 1H, NH), 8.84 (d, 1H, H-5, 4J = 2.6), 8.35 (dd, 1H, H-7, 3J = 9.1, 4J = 2.6), 8.40 (s, 1H, H-4), 7.60 (d, 1H, H-8, 3J = 9.1), 6.76-7.78 (5H, -Ph), 2.20 (s, 3H, CH3). 13C-NMR (DMSO-d6) δ: 159.2 (C-2), 157.1 (C-9), 144.4 (C-11), 144.2 (C-6), 137.7 (C-4), 137.5 (Ci), 130.6 (C-3), 129.6 (Cm), 126.1 (C-7), 124.2 (C-5), 121.5 (Cp), 119.9 (C-10), 117.7 (C-8), 113.6 (Co), 13.7 (Me). m/z = 322 (M, 20%), 246 (5%), 77 (15%).
6-Methoxy-3-[1-(phenylhydrazono)-ethyl]-chromen-2-one (1e). Obtained from 3-acetyl-6-methoxy-2H-1-benzopyran-2-one (0.5 g, 2.29 mmol) and phenylhydrazine (0.23 mL, 2.29 mmol) as an orange solid in 72% yield (0.512 g, 1.65 mmol), mp = 147–149 °C, IR νneat (cm−1): 3303 (N-H), 1698 (OC=O), 1574 (C=O), 1243, 1134 (C-O). 1H-NMR δ: 7.98 (s, 1H, H-4), 7.63 (s, 1H, NH), 7.24 (d, 1H, H-8, 3J = 8.1), 7.05 (dd, 1H, H-7, 3J = 9.1, 4J = 2.1), 6.86–7.30 (m, 5H,-Ph), 6.97 (d, 1H, H-5,4J = 2.4), 2.28 (s, 3H, CH3). 13C-NMR δ: 160.9 (C-2), 156.3 (C-6), 148.4 (C-9), 144.8 (C-11), 139.7 (C-4), 139.3 (Ci), 129.5 (Cm), 127.9 (C-3), 120.9 (Cp), 120.1 (C-10), 119.7 (C-7), 117.6 (C-8), 110.2 (C-5), 113.5 (Co), 14.1 (Me). m/z = 307 (M, 24%), 230 (5%), 77 (15%).
8-Methoxy-3-[1-(phenylhydrazono)-ethyl]-chromen-2-one (1f). Obtained from 3-acetyl-8-methoxy-2H-1-benzopyran-2-one (0.5 g, 2.29 mmol) and phenylhydrazine (0.23 mL, 2.29 mmol) as an orange solid in 91% yield (0.647 g, 2.09 mmol), mp = 152–156 °C, IR νneat (cm−1): 3306 (N-H), 1700 (OC=O), 1601 (C=O), 1263, 1160 (C-O). 1H-NMR δ: 8.02 (s, 1H, H-4), 7.59 (s, 1H, NH), 7.28 (d, 1H, H-7, 3J = 7.7), 7.17 (t, 1H, H-6, 3J = 7.7), 7.06 (d, 1H, H-5, 3J = 7.7), 6.87-7.36 (m, 5H, Ph), 2.29 (s, 3H, CH3). 13C-NMR δ: 160.2 (C-2), 147.1 (C-8), 144.7 (C-11), 140.0 (C-4), 143.5 (C-9), 139.3 (Ci), 129.5 (Cm), 127.9 (C-3), 124.6 (C-5), 120.9 (C-6), 120.4 (C-10), 120.0 (Cp), 113.5 (Co), 113.4 (C-7), 14.1 (Me). m/z = 306.2 (M, 100%), 230 (5%), 77 (17%).
6-Bromo-8-methoxy-3-[1-(phenylhydrazono)-ethyl]-chromen-2-one (1g). Obtained from 3-acetyl-6-bromo-8-methoxy-2H-1-benzopyran-2-one (0.5 g, 1.68 mmol) and phenylhydrazine (0.16 mL, 1.68 mmol) as an orange solid in 74% (0.485 g, 1.25 mmol), mp = 185–188 °C, IR νneat (cm−1) 3312 (N-H), 1713 (OC=O), 1599 (C=N), 1258 (C-O). 1H-NMR δ: 7.95 (s, 1H, H-4), 7.58 (s, 1H, NH), 7.34 (s, 1H, H-5), 7.24 (s, 1H, H-7), 6.84–7.29 (m, 5H, Ph), 2.28 (s, 3H, CH3), 3.96 (s, 3H, OMe). 13C-NMR δ: 156.3 (C-2), 151.6 (C-8), 147.8 (C-9), 144.5 (C-11), 138.5 (C-13), 138.3 (C-4), 129.5 (Cm), 128.8 (C-3), 121.1 (Cp), 122.0 (C-5), 121.4 (C-6), 116.9 (C-10), 116.5 (C-7), 113.5 (Co), 56.7 (MeO–), 13.8 (Me). m/z = 386 (M, 100%), 308 (5%), 77 (20%).
8-Bromo-6-chloro-3-[1-(phenylhydrazono)-ethyl]-chromen-2-one (1h). Obtained from 3-acetyl-8-bromo-6-chloro-2H-1-benzopyran-2-one (0.5 g, 1.66 mmol) and phenylhydrazine (0.16 mL, 1.66 mmol) as an orange solid in 84% yield (0.548 g, 1.39 mmol), mp = 199–201 °C, IR νneat (cm−1) 3312 (N-H), 1707 (OC=O), 1530 (C=N), 1248 (C-O). 1H-NMR δ: 7.95 (s, 1H, H-4), 7.62 (s, 1H, NH), 7.71 (d, 1H, H-7, 4J = 2.4), 7.51 (d, 1H, H-5, 4J = 2.4), 6.90-7.29 (m, 5H, Ph.), 2.29 (s, 3H, CH3). 13C-NMR δ:159.2 (C-2), 144.3 (C-11), 140.2 (C-9), 137.8.5 (C-13), 137.6 (C-4), 134.2 (C-7), 130.1 (C-6), 129.6 (C-14), 129.2 (C-3), 126.9 (C-5), 121.6 (C-10), 113.5 (C-15), 110.7 (C-8), 13.8 (Me). m/z = 390.1 (M, 100%), 391.1 (30%), 392.0 (25%), 315 (5%), 76.9 (30%).
6,8-Dichloro-3-[1-(phenylhydrazono)-ethyl]-chromen-2-one (1i). Obtained from 3-acetyl-6,8-dichloro-2H-1-benzopyran-2-one (0.5 g, 1.95 mmol) and phenylhydrazine (0.19 mL, 1.95 mmol) as an orange solid in 82% yield (0.557 mg, 1.60 mmol), mp = 196–198 °C, IR νneat (cm−1) 3311 (N-H), 1709 (OC=O), 1533 (C=N), 1162 (C-O). 1H-NMR δ: 7.96 (s, 1H, H-4), 7.62 (s, 1H, NH), 7.55 (d, 1H, H-7,4J = 2.2), 7.41 (2, 1H, H-5, 4J = 2.2), 6.94–7.30 (m, 5H, Ph), 2.29 (s, 3H, CH3). 13C-NMR δ: 159.0 (C-2), 151.3 (C-9), 144.3 (C-11), 138.8 (C-13), 137.6 (C-4), 134.2 (C-6), 131.3 (C-7), 129.8 (Cm), 129.7 (C-3), 124.2 (C-8), 121.6 (C-10), 121.3 (Cp), 113.6 (Co), 13.8 (Me). m/z = 347 (M, 20%), 346.3 (55%), 274 (8%), 77 (30%).
3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one (2a). Cu(CH3COO)2·H2O (0.025 g, 0.125 mmol) was dissolved in ethyl alcohol (20 mL) and added to a solution of 1a (0.500 g, 1.78 mmol) and ethyl alcohol (30 mL). The mixture was refluxed during 3 h, the resulting solid was filtered, washed with cold ethyl alcohol (5 mL) and several times with distilled water, air dried and recrystallized from ethyl acetate to obtain 0.372 mg (1.34 mmol) of 2a as a white powder in 76% yield, mp = 227–230 °C, IR νneat (cm−1): 1726 (OC=O), 1272, 1202 (C-O). 1H-NMR δ: 7.44 (t, 1H, H-7, 3J = 8.6, 4J = 1.6 Hz), 7.40 (d, 1H, H-6, 3J = 8.1), 7.09 (d, 1H, H-9, 3J = 7.9), 7.02 (t, 1H, H-8, 3J = 7.9, 4J = 1.6), 7.52–7.62 (m, 5H, Ph), 2.67 (s, 3H, CH3). 13C-NMR δ: 158.3 (C-4), 153.4 (C-5a), 151.0 (C-3), 141.9 (C-9b), 139.5 (Ci), 131.3 (C-7), 130.4 (Cp), 130.1 (Co), 127.0 (Cm), 124.1 (C-8), 122.6 (C-9), 118.2 (C-6), 112.0 (C-9a), 106.5 (C-3a), 13.1 (Me). m/z = 276.2 (M, 100%), 247.3 (5%), 206.2 (14%), 77.0 (16%).
8-Chloro-3-methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one (2b). Obtained as described for 2a starting from 1b (0.500 g, 1.59 mmol) to give 2b (0.343 g, 1.10 mmol, 69% yield) as a pale yellow powder, mp = 280–283 °C, IR νneat (cm−1): 1743 (OC=O), 1204 (C-O), 814 (C-Cl). 1H-NMR δ: 7.58 (dd, 1H, H-7 3J = 8.8, 4J = 1.9), 7.35 (d, 1H, H-6 3J = 8.8), 7.03 (d, 1H, H-9 4J = 1.9), 7.38–7.65 (m, 5H, Ph), 2.68 (s, 3H, CH3). 13C-NMR δ: 157.6 (C-4), 151.8 (C-5a), 151.2 (C-3), 140.7 (C-9b), 139.0 (Ci), 131.2 (C-7), 130.8 (C-p), 130.2 (C-o), 129.5 (C-8), 126.9 (C-m), 122.3 (C-9), 119.6 (C-6), 113.1 (C-9a), 106.8 (C-3a), 13.1 (Me). m/z = 310.2 (M, 100%), 311.0 (70%), 309.3 (45%), 275.3 (5%), 77 (22%).
8-Bromo-3-methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one (2c). Obtained as described for 2a starting from 1c (0.500 g, 1.39 mmol) to afford 2c (0.388 g, 1.09 mmol, 78% yield) as a white powder, mp = 278–280 °C, IR νneat (cm−1): 1742 (OC=O), 1266, 1203 (C-O). 1H-NMR δ: 7.52 (dd, 1H, H-7), 7.28 (d, 1H, H-6, 3J = 8.9), 7.16 (d, 1H, H-9 4J = 2.4), 7.54–7.78 (m, 5H, Ph), 2.67 (s, 3H, CH3). 13C-NMR δ: 157.6 (C-4), 152.3 (C-5a), 151.2 (C-3), 140.6 (C-9b), 139.0 (Ci), 134.0 (C-7), 130.8 (Cp), 130.3 (Co), 126.9 (Cm), 125.3 (C-9), 119.9 (C-8), 116.8 (C-6), 113.7 (C-9a), 106.8 (C-3a), 13.1 (Me). m/z = 354.3 (M, 80%), 356.1 (100%), 356.9 (35%), 358.0 (5%), 274.3 (5%), 77 (25).
3-Methyl-8-nitro-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one (2d). Obtained as described for 2a starting from 1d (0.500 g, 1.54 mmol) to give 2d (0.412 g, 1.28 mmol, 83% yield) as a pale yellow powder, mp = 248–254 °C, IR νneat (cm−1): 1756 (OC=O), 1259, 1207 (C-O), 1519 (C-NO2). 1H-NMR δ: 8.31 (dd, 1H, H-7, 3J = 9.1, 4J = 2.6), 8.02 (d, 1H, H-9 4J = 2.6), 7.55 (d, 1H, H-6, 3J = 9.1), 7.56–7.72 (m, 5H, Ph), 2.71 (s, 3H, CH3). 13C-NMR δ: 156.9 (C-4), 156.6 (C-5a), 151.5 (C-3), 143.6 (C-9b), 140.2 (C-8), 138.6 (Ci), 131.2 (Cp), 130.6 (Co), 126.7 (Cm), 126.0 (C-7), 119.3 (C-9), 118.8 (C-6), 112.4 (C-9a), 106.8 (C-3a), 13.1 (Me). m/z = 321.0 (M, 100%), 320.2 (25%), 322.9 (5%), 275.3 (10%), 77 (21%).
8-Methoxy-3-methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one (2e). Obtained as described for 2a starting from 1e (0.500 g, 1.61 mmol) to obtain 2e (0.258 g, 0.84 mmol, 52% yield) as a white powder, mp = 232–234 °C, IR νneat (cm−1): 1734 (OC=O), 1238, 1203 (C-O). 1H-NMR δ: 7.32 (d, 1H, H-6,3J = 9.0), 6.98 (dd, 1H, H-7, 3J = 9.0, 4J = 3.1), 6.50 (d, 1H, H-9, 4J = 3.1), 7.63-7.54 (m, 5H, Ph), 2.68 (s, 3H, CH3). 13C-NMR δ: 158.4 (C-4), 155.6 (C-8), 151.0 (C-3), 147.9 (C-5a), 141.9 (C-9b), 139.5 (Ci), 130.5 (Co), 130.5 (Cp), 127.4 (Cm), 119.2 (C-7), 118.8 (C-6), 112.1 (C-9a), 106.7 (C-3a), 105.5 (C-9), 13.4 (Me). m/z = 306.1 (M, 100%), 291.3 (28%), 277 (3%), 77 (22%). Anal. Calcd. for C18H14N2O3; C, 70.58; H, 4.61; N, 9.14. Found: C, 70.22; H, 4.50; N, 9.00.
6-Methoxy-3-methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one (2f). Obtained as described for 2a starting from 1f (0.500 g, 1.61 mmol) to give 2f (0.248 g, 0.806 mmol, 50% yield) as a white powder, mp = 238–240 °C, IR νneat (cm−1): 1743 (OC=O), 1273, 1207 (C-O). 1H-NMR δ: 7.02 (dd, 1H, H-7,3J = 8.2, 7.6), 6.97 (t, 1H, H-8, 3J = 7.6, 8.2), 6.65 (dd, 1H, H-9 3J = 7.6, 4J = 1.5), 7.54–7.62 (m, 5H, Ph), 2.69 (s, 3H, CH3). 13C-NMR δ: 157.6 (C-4), 151.0 (C-3), 148.4 (C-6), 143.3 (C-5a), 142.1 (C-9b), 139.6 (Ci), 130.4 (Cp), 130.0 (Co), 127.2 (Cm), 123.9 (C-8), 114.1 (C-9), 112.9 (C-7), 112.7 (C-9a), 106.6 (C-3a), 13.2 (Me). m/z = 306.1 (M, 100%), 291.3 (5%), 277 (20%), 77 (22%). Anal. Calcd. for C18H14N2O3; C, 70.58; H, 4.61; N, 9.14. Found: C, 70.83; H, 4.70; N, 9.00.
8-Bromo-3-methyl-6-methoxy-1H-chromeno[4,3-c]pyrazol-4-one (2g). Obtained as described for 2a starting from 1g (0.500 g, 1.28 mmol) to obtain 2g (0.393 g, 1.01 mmol, 79% yield) as a pale yellow powder, mp = 289–292 °C, IR νneat (cm−1): 1744 (OC=O), 1275, 1205 (C-O). 1H-NMR δ: 6.72 (s, 1H, H-9), 7.06 (s, 1H, H-6), 7.51-7.62 (m, 5H, Ph), 2.67 (s, 3H, CH3). 13C-NMR δ: 156.7 (C-4), 151.1 (C-5a), 148.9 (C-3), 142.3 (C-6), 140.1 (C-9b), 139.0 (C-10), 130.7 (C-9), 130.1 (C-11), 127.0 (C-12), 123.9 (C-5), 123.3 (C-8), 116.5 (C-13), 116.1 (C-7), 113.7 (C-9a), 106.8 (C-3a), 13.1 (Me). m/z = 384.5 (M, 80%), 386.2 (100%), 385.5 (25%), 357.5 (10%), 290.5 (10%), 77.0 (25%). Anal. Calcd. for C18H13N2O3Br; C, 56.13; H, 3.40; N, 7.27. Found: C, 55.88; H, 3.40; N, 7.20.
6-Bromo-8-Chloro-3-methyl-1H-chromeno[4,3-c]pyrazol-4-one (2h). Obtained as described for 2a starting from 1h (0.5 g, 1.27 mmol) to obtain 2h (0.249 g, 0.64 mmol, 50% yield) as a pale yellow powder, mp = 259–261 °C, IR νneat (cm−1): 1749 (OC=O), 1277, 1224 (C-O). 1H-NMR δ: 6.90 (s, 1H, H-9), 7.82 (s, 1H, H-7), 7.53-7.65 (m, 5H, Ph), 2.65 (s, 3H, CH3). 13C-NMR δ: 156.2 (C-4), 151.1 (C-5a), 148.2 (C-3), 140.2 (C-9b), 138.8 (C-10), 134.2 (C-7), 130.9 (C-9), 130.6 (C-11), 129.5 (C-8), 126.9 (C-12), 121.4 (C-13), 113.9 (C-6), 112.6 (C-9a), 106.8 (C-3a), 13.0 (Me). m/z = 390.0 (M, 100%), 389.5 (60%), 388.5 (62%), 310 (5%), 77(25%). Anal. Calcd. for C17H10N2O2BrCl; C, 52.40; H, 2.59; N, 7.19. Found: C, 52.70; H, 2.63; N, 7.00.
6,8-Dichloro-3-methyl-1H-chromeno[4,3-c]pyrazol-4-one (2i). Obtained as described for 2a starting from 1i (0.5 g, 1.43 mmol) to obtain 2i (0.259 g, 0.74 mmol, 52% yield) as a pale yellow powder, mp = 224–226 °C, IR νneat (cm−1): 1750 (OC=O), 1225 (C-O). 1H-NMR δ: 6.90 (s, 1H, H-9), 7.47 (s, 1H, H-7), 7.52-7.64 (m, 5H, Ph), 2.65 (s, 3H, CH3). 13C-NMR δ: 156.2 (C-4), 151.1 (C-5a), 147.8 (C-3), 140.2 (C-9b), 138.8 (C-10), 131.3 (C-7), 130.9 (C-9), 130.3 (C-11), 129.1 (C-8), 126.9 (C-12), 124.1 (C-6), 120.8 (C-13), 114.0 (C-9a), 106.8 (C-3a), 13.0 (Me). m/z = 344.5 (M, 100%), 346.2 (80%), 345.3 (68%), 308.5, 77 (22%). Anal. Calcd. for C17H10N2O2Cl2; C, 59.15; H, 2.92; N, 8.11. Found: C, 58.90; H, 2.89; N, 8.00.

4. Conclusions

3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one (2a) spontaneously crystallizes from CHCl3solutions of 3-[1-(phenyl-hydrazono)-ethyl]-chromen-2-one (1a) whereas the 6-substituted isomers 1b-i failed to do so, requiring Cu(CH3COO)2·H2O as catalyst to yield the corresponding 1-phenyl-chromeno[4,3-c]pyrazol-4-ones 2b-i in moderate to good yields (50–83%) under mild conditions. The NMR data in solution and the X-ray data in the solid state are consistent with the N-phenyl ring almost perpendicular to the three fused rings chromeno-pyrazole system. In the solid state this geometrical arrangement of the aromatic rings determines the supramolecular architecture by C―H···A (A = O, π) and face to face π-stacking interactions which are very similar among 2b-d, varying only in the nature of the π-stacked rings and in the propagating direction. The observed π-stacking trend between chromeno and pyrazole rings is given by the overlapping between the best donor and acceptor rings in each molecule, modulated by the electronic character of the X and Y substituents.

Acknowledgements

Authors thanks to CONACYT project 83378, Secretaria de Investigación y Posgrado del Instituto Politécnico Nacional and Fondos FRABA for financial support, and Centro de Investigaciones Químicas de la Universidad Autónoma del Estado de Morelos for the CSD license.

References and Notes

  1. Behr, L.C.; Fusco, R.; Jarboe, C.H. Pyrazoles, pyrazolines, pyrazolidines, indazoles and condensed rings; Wiley-Interscience Publishers: New York, NY, USA, 1967; pp. 10–16. [Google Scholar]
  2. Elguero, J. Comprehensive Heterocyclic Chemistry; Katritsky, A.R., Rees, C.W., Eds.; Pergamon: Oxford, UK, 1984; Volume 5, pp. 167–303. [Google Scholar]
  3. Tanitame, A.; Oyamada, Y.; Ofuji, K.; Fujimoto, M.; Iwai, N.; Hiyama, Y.; Susuki, K.; Ito, H.; Terauchi, H.; Kawasaki, M.; Nagai, K.; Wachi, M.; Yamagishi, J. Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives. J. Med. Chem. 2004, 47, 3693–3696. [Google Scholar]
  4. Bekhit, A.A.; Ashour, H.M.A.; Guemei, A.A. Novel pyrazole derivatives as potential promising anti-inflammatory antimicrobial agents. Arch. Pharm. 2005, 338, 167–174. [Google Scholar] [CrossRef]
  5. Goodell, J.R.; Puig-Basagoiti, F.; Forshey, B.; Shi, P.; Ferguson, D. Identification of compounds with anti-west nile virus activity. J. Med. Chem. 2006, 49, 2127–2137. [Google Scholar] [CrossRef]
  6. Lougiakis, N.; Marakos, P.; Poul, N.; Balzarani, J. Synthesis and antiviral activity evaluation of some novel acyclic C-nucleosides. Chem. Pharm. Bull. 2008, 56, 775–780. [Google Scholar] [CrossRef]
  7. Roppe, J.; Smith, N.D.; Huang, D.; Tehrani, L.; Wang, B.; Anderson, J.; Brodkin, J.; Chung, J.; Jiang, X.; King, C.; Munoz, B.; Varney, M.; Prasit, P.; Cosford, N. Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J. Med. Chem. 2004, 47, 4645–4648. [Google Scholar]
  8. Melani, F.; Cecchi, L.; Palazzino, G.; Filiacchioni, G.; Pennacchi, E; Lucacchini, A. Pyrazolo[4,5-c]quinolines. 2. Synthesis and specific inhibition of bezodiazepine receptor binding. J. Med. Chem. 1986, 29, 291–295. [Google Scholar] [CrossRef]
  9. Khode, S.; Maddi, V.; Aragede, P.; Palkar, M.; Kumar, R.P.; Mamledesai, S.; Thippeswamy, A.H.M.; Satyanarayana, D. Synthesis and pharmacological evaluation of a novel series of 5-(substituted) aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents. Eur. J. Med. Chem. 2009, 44, 1682–1688. [Google Scholar]
  10. Ren, X.L.; Li, H.B.; Wu, C.; Yang, H.Z. Synthesis of a small library containing substituted pyrazoles. Arkivoc 2005, 15, 59–67. [Google Scholar]
  11. Li, H.B.; Zhu, Y.Q.; Song, X.W.; Hu, F.Z.; Liu, B.; Li, Y.H.; Niu, Z.X.; Liu, P.; Wang, Z.H.; Song, H.B.; Zou, X.M.; Yang, H.Z. Novel protoporphyrinogen oxidase inhibitors: 3H-pyrazolo[3,4-d][1,2,3]triazin-4-one derivatives. J. Agric. Food Chem. 2008, 56, 9535–9542. [Google Scholar]
  12. Meegalla, S.K.; Doller, D.; Sha, D.Y.; Soll, R.; Wisnewski, N.M.; Silver, G.M.; Dhanoa, D. Synthesis and GABA receptor potency of 3-thiomethyl-4-(hetero)aryl-5-amino-1-phenylpyrazoles. Bioorg. Med. Chem. 2004, 14, 4949–4953. [Google Scholar] [CrossRef]
  13. Colotta, V.; Cecchi, L.; Filacchioni, G.; Melani, F.; Palazzino, G.; Martini, C.; Giannaccini, G.; Lucaccini, A. Synthesis, binding studies and structure-activity relationships of 1-aryl- and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ligands. J. Med. Chem. 1988, 31, 1–3. [Google Scholar] [CrossRef]
  14. Kidwai, M.; Singhal, P.K.; Rastogi, S. A convenient K2CO3 catalysed regioselective synthesis for benzopyrano[4,3-c]pyrazoles in aqueous medium. Heterocycles 2007, 71, 569–576. [Google Scholar] [CrossRef]
  15. Chantegrel, B.; Nadi, A.-I.; Gelin, S. 4-Oxo-1H- and 2H-[1]benzopyrano[4,3-c]pyrazoles. Preparation from 4-hydroxycoumarin or 3-chromonecarboxylic acid derivatives. Tetrahedron Lett. 1983, 24, 381–384. [Google Scholar] [CrossRef]
  16. Colotta, V.; Cecchi, L.; Melani, F.; Palazzino, G.; Filacchioni, G. The correct synthesis of 2,3-dihydro-2-aryl-4-R-[1]benzopyrano[4,3-c]pyrazole-3-ones. Tetrahedron Lett. 1987, 28, 5165–5168. [Google Scholar] [CrossRef]
  17. Stadlbauer, W.; Hojas, G. Ring closure reactions of 3-arylhydrazonoalkyl-quinolin-2-ones to 1-aryl-pyrazolo[4,3-c]quinolin-2-ones. J. Heterocycl. Chem. 2004, 41, 681–690. [Google Scholar] [CrossRef]
  18. Hassan, N.A.; Mohamed, T.K.; Abdel-Hafez, O.M.; Lutz, M.; Karl, C.C.; Wirschun, W.; Al-Soud, Y.A.; Jochims, J.C. Cycloadditions of 1-aza-2-azoniaallene salts derived from coumarin and camphor. J. Prakt. Chem. 1998, 340, 151–159. [Google Scholar] [CrossRef]
  19. Hassaneen, H.M.; Mousa, H.A.H.; Shawali, A.S. Chemistry of C-heteroarylnitrilimines. Synthesis and cycloaddition reactions of N-phenyl-C-(2-thienyl)nitrilimine. J. Heterocycl. Chem. 1987, 24, 1665–1668. [Google Scholar] [CrossRef]
  20. Allen, F.H. The Cambridge Structural Database: a quarter of million crystal structures and rising. Acta Cryst. 2002, B58, 380–388. [Google Scholar]
  21. Hamada, T.; Ye, X.; Stahl, S.S. Copper-catalyzed aerobic oxidative amidation of terminal alkynes: efficient synthesis of ynamides. J. Am. Chem. Soc. 2008, 130, 833–835. [Google Scholar] [CrossRef]
  22. Monguchi, D.; Fujiwara, T.; Furukawa, H.; Mori, A. Direct amination of azoles via catalytic C-H, N-H Coupling. Org. Lett. 2009, 11, 1607–1610. [Google Scholar] [CrossRef]
  23. Colotta, V.; Cecchi, L.; Melani, F.; Filacchioni, G.; Martini, C.; Gelli, S.; Lucacchini, A. Triciclyc heteroaromatic systems: [1]bezopyrano-pyrazol-4-ones as benzodiazepine receptor ligans. J. Pharm. Sci. 1991, 80, 276–279. [Google Scholar] [CrossRef]
  24. Braun, N.A.; Ousmer, M.; Bray, J.D.; Bouchu, D.; Peters, K.; Peters, E.-M.; Ciufolini, M.A. New oxidative transformations of phenolic and indolic oxazolines: an avenue to useful azaspirocyclic building blocks. J. Org. Chem. 2000, 65, 4397–4408. [Google Scholar]
  25. Dang, T.-T.; Dang, T.-T.; Langer, P. One-pot synthesis of pyrazole-5-carboxylates by cyclization of hydrazone 1,4-dianions with diethyl oxalate. Tetrahedron Lett. 2007, 48, 3591–3593. [Google Scholar] [CrossRef]
  26. Santos-Contreras, R.; Martínez-Martínez, F.J.; Padilla-Martínez, I.I.; Peraza, A.L.; Höpfl, H. Carbonyl-carbonyl, carbonyl-pi and carbonyl-halogen dipolar interactions as the directing motifs of the supramolecular structure of ethyl 6-chloro-2-oxo-2H-chromene-3-carboxylate and ethyl 6-bromo-2-oxo-2H-chromene-3-carboxylate. Acta Cryst. 2007, C63, o239–o242. [Google Scholar]
  27. Strakova, I.; Petrova, M.; Belyakov, S.; Strakovs, A. Reactions of 4-chloro-3-formylcoumarin with arylhydrazines. Chem. Heterocycl. Comp. 2003, 39, 1608–1616. [Google Scholar] [CrossRef]
  28. Chopra, D.; Venugopala, K.N.; Rao, G.K.; Row, T.N.G. 3-Dibromoacetyl-2H-chromen-2-one. Acta Cryst. 2007, E63, o2826–o1971. [Google Scholar]
  29. Umezawa, Y.; Tsuboyama, S.; Honda, K.; Uzawa, J.; Nishio, M. CH/π Interaction in the crystal structure of organic compounds. A database study. Bull. Chem. Soc. Jpn. 1998, 71, 1207–1213. [Google Scholar] [CrossRef]
  30. Bernstein, J.; Davis, R.E.; Shimoni, L.; Chang, N.L. Patterns in hydrogen bonding: functionality and graph set analysis in crystals. Angew. Chem. Int. Ed. Engl. 1995, 34, 1555–1573. [Google Scholar] [CrossRef]
  31. Williams, J.H. The molecular electric quadrupole moment and solid-state architecture. Acc. Chem. Res. 1993, 26, 593–598. [Google Scholar] [CrossRef]
  32. Kovalevsky, A.Y. CCDC private communication, 2000.
  33. Allen, F.H.; Baalham, C.A.; Lommerse, J.P.M.; Raithby, P.R. Carbonyl-carbonyl interactions can be competitive with hydrogen bonds. Acta Cryst. 1998, B54, 320–329. [Google Scholar]
  34. García-Báez, E.V.; Martínez-Martínez, F.J.; Höpfl, H.; Padilla-Martínez, I.I. Pi-stacking interactions and C-H···X (X = O, aryl) hydrogen bonding as directing features of the supramolecular self-association in 3-carboxy and 3-amido coumarin derivatives. Cryst. Growth. Des. 2003, 3, 34–45. [Google Scholar]
  35. Santos-Contreras, R.J.; Martínez-Martínez, F.J.; Mancilla-Margalli, N.A.; Peraza-Campos, A.L.; Morín-Sánchez, L.M.; García-Báez, E.V.; Padilla-Martínez, I.I. Competition between OH···O and multiple halogen-dipole interactions on the formation of intramolecular three-centred hydrogen bond in 3-acyl coumarins. CrystEngCommunity 2009, 11, 1451–1461. [Google Scholar] [CrossRef]
  36. Flores-Larios, I.Y.; López-Garrido, L.; Martínez-Martínez, F.J.; González, J.; García-Báez, E.V.; Cruz, A.; Padilla-Martínez, I.I. Thermal [4+2] Cycloadditions of 3-acetyl-, 3-carbamoyl-, and 3-ethoxycarbonyl-coumarins with 2,3-dimethyl-1,3-butadiene under solventless conditions: a structural study. Molecules 2010, 15, 1513–1530. [Google Scholar] [CrossRef]
  37. Bruker. APEX II, SAINT, SADABS and SHELXTL, Bruker AXS Inc: Madison, WI, USA, 2004.
  38. Sheldrick, G.M. A short history of SHELX. Acta Cryst. 2008, A64, 112–122. [Google Scholar]
  39. Farrugia, L.J. WinGX suite for small-molecule single-crystal crystallography. J. Appl. Cryst. 1999, 32, 837–838. [Google Scholar] [CrossRef]
  40. Macrae, C.F.; Edgington, P.R.; McCabe, P.; Pidcock, E.; Shields, G.P.; Taylor, R.; Towler, M.; van de Streek, J. Mercury: visualization and analysis of crystal structures. J. Appl. Cryst. 2006, 39, 453–457. [Google Scholar] [CrossRef]
  41. Spek, A.L. Single-crystal structure validation with the program. J. Appl. Cryst. 2003, 36, 7–13. [Google Scholar] [CrossRef]
  • Sample Availability: Samples of the compounds 2e-i are available from the authors.

Share and Cite

MDPI and ACS Style

Padilla-Martinez, I.I.; Flores-Larios, I.Y.; García-Baez, E.V.; Gonzalez, J.; Cruz, A.; Martínez-Martinez, F.J. X-Ray Supramolecular Structure, NMR Spectroscopy and Synthesis of 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-ones Formed by the Unexpected Cyclization of 3-[1-(Phenyl-hydrazono)ethyl]-chromen-2-ones. Molecules 2011, 16, 915-932. https://doi.org/10.3390/molecules16010915

AMA Style

Padilla-Martinez II, Flores-Larios IY, García-Baez EV, Gonzalez J, Cruz A, Martínez-Martinez FJ. X-Ray Supramolecular Structure, NMR Spectroscopy and Synthesis of 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-ones Formed by the Unexpected Cyclization of 3-[1-(Phenyl-hydrazono)ethyl]-chromen-2-ones. Molecules. 2011; 16(1):915-932. https://doi.org/10.3390/molecules16010915

Chicago/Turabian Style

Padilla-Martinez, Itzia I., Irma Y. Flores-Larios, Efren V. García-Baez, Jorge Gonzalez, Alejandro Cruz, and Francisco J. Martínez-Martinez. 2011. "X-Ray Supramolecular Structure, NMR Spectroscopy and Synthesis of 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-ones Formed by the Unexpected Cyclization of 3-[1-(Phenyl-hydrazono)ethyl]-chromen-2-ones" Molecules 16, no. 1: 915-932. https://doi.org/10.3390/molecules16010915

Article Metrics

Back to TopTop